More than half of its gross sales ultimately went to payers as rebates, Sanofi says

In a new report, Sanofi is adding another data point to one of pharma’s go-to defenses regarding their pricing practices.

As much as 55% of its gross sales in 2019 were given back to payers in the form of rebates, the pharma giant disclosed, including $5.5 billion in mandatory rebates to the government and $8.4 billion in discretionary rebates to insurance companies.